Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2020-03, Vol.22 (3), p.355-364
Main Authors: Matza, Louis S., Boye, Kristina S., Stewart, Katie D., Coyne, Karin S., Wullenweber, Paula K., Cutts, Katelyn N., Jordan, Jessica B., Wang, Qianqian, Yu, Maria, Currie, Brooke M., Malley, Karen G., Ishak, K. Jack, Hietpas, Ryan T., García‐Pérez, Luis‐Emilio
Format: Article
Language:English
Subjects:
Antidiabetics
Cross-Over Studies
crossover study
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
dulaglutide
Female
GLP-1 receptor agonists
Glucagon-Like Peptides - analogs & derivatives
Humans
Hypoglycemic Agents
Immunoglobulin Fc Fragments
Injection
injection devices
Male
Middle Aged
Obesity
Original
Patient Preference
Patients
preference
Recombinant Fusion Proteins
semaglutide
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1 receptor agonists. Materials and Methods The PREFER study was an open‐label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection‐naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time‐to‐train (TTT) for each device was assessed in a subset. Results There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13902